The Efficacy and Safety of Cilostazol in Ischemic Stroke Patients with Peripheral Arterial Disease (SPAD): Protocol of a Randomized,Double-Blind,Placebo-Controlled Multicenter Trial

Abstract

Rationale

It is not uncommon for patients with ischemic stroke to have peripheral arterial disease (PAD). Patients with polyvascular diseases carry greater burden of atherosclerosis and higher risks of developing vascular events and death. More effective regimens, such as dual antiplatelet agents, may be more effective for controlling progression of atherosclerosis in secondary prevention.

Aim

This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease.

Design

The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients with Peripheral Arterial Disease (SPAD) study is a randomized double-blinded placebo-controlled trial. Patients with previous ischemic stroke or TIA who had been taking aspirin (100 mg per day), aged 50 years or older, with PAD in the lower limbs based on ankle-brachial index (ABI) <1·0 will be randomized into the treatment group with cilostazol (200 mg/day) or the placebo group on 1:1 basis.

Study outcomes

Patients will be evaluated at 1, 3, 6, 9 and 12 months after randomization. The primary endpoint is difference in change in ABI between groups. The secondary and tertiary endpoints are the difference between groups in change in carotid intima-media thickness (IMT) and incidence rate of major cardiovascular events, including recurrent stroke, myocardial infarction, unstable angina, other vascular events, and death; and the safety measures, including major bleeding events, hemorrhagic stroke and death of any cause.

Conclusion

The SPAD trial is the first study to evaluate the safety and efficacy of dual antiplatelet agents, aspirin plus cilostazol, in comparison with aspirin alone in patients with both ischemic stroke or TIA and PAD. Results from this trial will provide important information on the merit of adding cilostazol to aspirin for slowing down progression of atherosclerosis in patients with ischemic stroke and PAD.

Keywords

ankle-brachial index aspirin cilostazol intima-media thickness ischemic stroke peripheral arterial disease

Get full access to this article

View all access options for this article.

References

Banerjee

Fowkes

Rothwell

. Associations between peripheral artery disease and ischemic stroke: implications for primary and secondary prevention. Stroke 2010; 41:2102–7.

Carolei

Chamorro

Laloux

. Identification and management of polyvascular disease in patients with noncardioembolic ischaemic stroke. Int J Stroke 2008; 3:237–48.

Röther

Alberts

Touzé

. Risk factor profile and management of cerebrovascular patients in the REACH Registry. Cerebrovasc Dis 2008; 25:366–74.

Ovbiagele

. Association of ankle-brachial index level with stroke. J Neurol Sci 2009; 276:14–7.

Bhatt

Steg

Ohman

. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295:180–9.

Leys

Woimant

Ferrières

. Detection and management of associated atherothrombotic locations in patients with a recent atherothrombotic ischemic stroke: results of the DETECT survey. Cerebrovasc Dis 2006; 21:60–6.

Weimar

Goertler

Röther

. Systemic Risk Score Evaluation in Ischemic Stroke Patients (SCALA): a prospective cross sectional study in 85 German stroke units. J Neurol 2007; 254:1562–8.

Roquer

Ois

Rodríguez-Campello

. Atherosclerotic burden and early mortality in acute ischemic stroke. Arch Neurol 2007; 64:699–704.

Agnelli

Cimminiello

Meneghetti

Urbinati

. Low ankle–brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events. J Thromb Haemost 2006; 4:2599–606.

10.

Topakian

Nanz

Rohrbacher

Koppensteiner

Aichner

, OECROSS Study Group. High prevalence of peripheral arterial disease in patients with acute ischaemic stroke. Cerebrovasc Dis 2010; 29:248–54.

11.

Berger

Krantz

Kittelson

Hiatt

. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009; 301:1909–19.

12.

Mozaffarian

Roger

. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 2013; 127:e6–245.

13.

Mohan

Wolfe

Rudd

Heuschmann

Kolominsky-Rabas

Grieve

. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 2011; 42:1489–94.

14.

Busch

Lutz

Rohl

Neuner

Masuhr

. Low ankle-brachial index predicts cardiovascular risk after acute ischemic stroke or transient ischemic attack. Stroke 2009; 40:3700–5.

15.

Tsivgoulis

Bogiatzi

Heliopoulos

. Low ankle-brachial index predicts early risk of recurrent stroke in patients with acute cerebral ischemia. Atherosclerosis 2012; 220:407–12.

16.

Manzano

De Silva

Pascual

Chang

Wong

Chen

. Associations of ankle-brachial index (ABI) with cerebral arterial disease and vascular events following ischemic stroke. Atherosclerosis 2012; 223:219–22.

17.

Lackland

Elkind

D'Agostino

Sr . Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012; 43:1998–2027.

18.

Antithormbotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71–86.

19.

Antithrombotic Trialists' (ATT) Collaboration, Baigent

Blackwell

. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849–60.

20.

Basili

Raparelli

Vestri

Di Tanna

Violi

. Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis. Thromb Haemost 2010; 103:766–73.

21.

Goto

. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 2005; 6:3–11.

22.

Ikeda

Sudo

Kimura

. Cilostazol; in Michelson

(ed.): Platelets, 2th edn. Amsterdam, Elsevier, 2006:1181–91.

23.

Pearce

Ghosh

Counsell

Serracino-Inglott

. Cilostazol and peripheral arterial disease. Expert Opin Pharmacother 2008; 9:2683–90.

24.

Anderson

Halperin

Albert

. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:1425–43.

25.

Shinohara

Katayama

Uchiyama

. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9:959–68.

26.

Fowkes

Rudan

. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382:1329–40.

27.

Shirai

Utino

Otsuka

Takata

. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb 2006; 13:101–7.

28.

Espinola-Klein

Rupprecht

Bickel

. Different calculations of ankle-brachial index and their impact on cardiovascular risk prediction. Circulation 2008; 118:961–7.

29.

Katakami

Kim

Kawamori

Yamasaki

. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 2010; 121:2584–91.

30.

Money

Herd

Isaacsohn

. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27:267–75.

31.

Alberts

Bhatt

Mas

. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J 2009; 30:2318–26.

32.

Steg

Bhatt

Wilson

. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297:1197–206.

33.

Palacio

Hart

Pearce

. Effect of addition of clopidogrel to aspirin on stroke incidence: meta-analysis of randomized trials. Int J Stroke 2013. doi: 10.1111/ijs.12050.

34.

Diener

Bogousslavsky

Brass

. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:331–7.

35.

Bhatt

Fox

Hacke

. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706–17.

36.

Poredo

Jezovnik

. Is aspirin still the drug of choice for management of patients with peripheral arterial disease? Vasa 2013; 42:88–95.

37.

Uchiyama

Demaerschalk

Goto

. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis 2009; 18:482–90.

38.

Kwon

Cho

Koo

. Cilostazol prevents the progression of the symptomatic intracranial arterial symptomatic intracranial arterial stenosis: the Multicenter Double-Blind Placebo-Controlled Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis. Stroke 2005; 36:782–6.

39.

Olin

Allie

Belkin

. 2010 performance measures for adults with peripheral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on performance measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery. Circulation 2010; 122:2583–618.

40.

Lorenz

Markus

Bots

Rosvall

Sitzer

. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115:459–67.